Skip to content
Screener

Iovance Biotherapeutics, Inc. IOVA Net gains (losses) on investments

Net gains (losses) on investments at other companies

Gilead Sciences logo
Gilead SciencesGILD
$253M+301%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$180K-1,536%
Incyte logo
IncyteINCY
$9.81M+336%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$329K-75.4%

Other financials

Income statement

See full
Revenue$99.3M+65.7%
Gross profit$55.7M+403%
Operating income-$51.9M+54.4%
Net income-$47.3M+57.6%
EPS (diluted)-$0.11+66.7%

Balance sheet

See full
Cash & equivalents$110.8M-16.4%
Total debt$46.0M-11.8%
Total equity$736.0M+5.4%
Total assets$915.5M+0.9%

Cash flow

See full
Operating cash flow-$60.8M+9.8%
CapEx$5.4M-27.1%
Free cash flow-$66.3M+11.5%

Valuation

See full
Market cap$2.9B+307%
Enterprise value$2.83B+348%
P/S8.9×+6.0×

Profitability

See full
Gross margin48.4%+15.0pp
Operating margin-92.7%-29.0pp
Net margin-89.1%-27.6pp
FCF margin-91.2%-22.1pp

Returns & leverage

See full
Return on equity-40.4%-7.8pp
Debt / equity0.1×0.0×
Current ratio4.3×+1.1×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.

The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 9:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091716
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Net increase (decrease) in cash, cash equivalents and restricted cash(52,285)16,360
Cash, Cash Equivalents and Restricted Cash Beginning of Period169,058122,053
Cash, Cash Equivalents and Restricted Cash End of Period$116,773$138,413
Supplemental disclosure of non-cash investing and financing activities:
Net unrealized loss on investments137140
Acquisition of property and equipment included in accounts payable and accrued expenses5,17113,283
Conversion of convertible preferred stock to common stock1
Increase in lease liabilities due to obtaining right-of-use assets from lease modifications359496

Item 1.Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Iovance Biotherapeutics, Inc.'s net gains (losses) on investments?
Iovance Biotherapeutics, Inc. (IOVA) reported net gains (losses) on investments of $52K in Q2 2026.
How has Iovance Biotherapeutics, Inc.'s net gains (losses) on investments changed year-over-year?
Iovance Biotherapeutics, Inc.'s net gains (losses) on investments increased by 73.3% year-over-year, from $30K to $52K.
What does net gains (losses) on investments mean?
Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.

Ask your AI about Iovance Biotherapeutics, Inc.'s net gains (losses) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude